Schreyer, Korbinian Felix http://orcid.org/0000-0001-9473-3958
Leucht, Stefan
Heres, Stephan
Steimer, Werner
Funding for this research was provided by:
Bundesministerium für Bildung und Forschung (01KG0910)
Technische Universität München
Article History
Received: 16 May 2022
Accepted: 30 January 2023
First Online: 9 February 2023
Declarations
:
: Korbinian Felix Schreyer declares no conflict of interest. In the past 3 years, Stefan Leucht has received honoraria as a consultant and/or advisor and/or for lectures from Alkermes, Angelini, Eisai, Gedeon Richter, Janssen, Lundbeck, Lundbeck Institute, Merck Sharp and Dohme, Otsuka, Recordati, Rovi, Sanofi Aventis, TEVA, Medichem, and Mitsubishi. Stephan Heres has received lecture honoraria from Janssen-Cilag, Sanofi-Aventis, Bristol-Myers-Squibb, Eli Lilly, and Johnson & Johnson. Stephan Heres acts as consultant and/or participates in board meetings of Janssen-Cilag, Eli Lilly, Roche, Lundbeck, and Johnson & Johnson. Stephan Heres has accepted travel or hospitality payment from Janssen-Cilag, Sanofi-Aventis, Johnson & Johnson, Pfizer, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Novartis, and Eli Lilly. Stephan Heres participated in clinical trials sponsored or supported by Eli Lilly, Janssen-Cilag, Johnson & Johnson, Bristol-Myers Squibb, AstraZeneca, Lundbeck, Novartis, Servier, Pierre Fabre, Pfizer, Roche, Shire, and Merck. Werner Steimer is consultant to INSTAND e.V. Werner Steimer is unpaid member and chair of the DGKL section “Therapeutisches Drug Monitoring und Klinische Toxikologie“.